Xinxiang Tuoxin Pharmaceutical Co.Ltd. - Asset Resilience Ratio

Latest as of March 2026: 7.00%

Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) has an Asset Resilience Ratio of 7.00% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 301089 financial flexibility index to measure the company's free cash flow as a share of total liabilities.

Liquid Assets

CN¥115.56 Million
≈ $16.91 Million USD Cash + Short-term Investments

Total Assets

CN¥1.65 Billion
≈ $241.59 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s Asset Resilience Ratio has changed over time. See how leveraged is Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s balance sheet to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥115.56 Million 7.0%
Total Liquid Assets CN¥115.56 Million 7.00%

Asset Resilience Insights

  • Limited Liquidity: Xinxiang Tuoxin Pharmaceutical Co.Ltd. maintains only 7.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Xinxiang Tuoxin Pharmaceutical Co.Ltd. Industry Peers by Asset Resilience Ratio

Compare Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
SIMCERE PHARMAC. GRP LTD
F:S2P
Drug Manufacturers - Specialty & Generic 0.44%
Curaleaf Holdings Inc.
TO:CURA
Drug Manufacturers - Specialty & Generic 3.73%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Walvax BioTech
SHE:300142
Drug Manufacturers - Specialty & Generic 2.20%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%

Annual Asset Resilience Ratio for Xinxiang Tuoxin Pharmaceutical Co.Ltd. (2021–2025)

The table below shows the annual Asset Resilience Ratio data for Xinxiang Tuoxin Pharmaceutical Co.Ltd..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 6.31% CN¥105.15 Million
≈ $15.39 Million
CN¥1.67 Billion
≈ $243.69 Million
-7.95pp
2024-12-31 14.27% CN¥250.88 Million
≈ $36.71 Million
CN¥1.76 Billion
≈ $257.29 Million
+3.90pp
2023-12-31 10.37% CN¥190.70 Million
≈ $27.91 Million
CN¥1.84 Billion
≈ $269.10 Million
-2.66pp
2022-12-31 13.03% CN¥240.16 Million
≈ $35.14 Million
CN¥1.84 Billion
≈ $269.73 Million
-2.80pp
2021-12-31 15.83% CN¥220.62 Million
≈ $32.28 Million
CN¥1.39 Billion
≈ $203.94 Million
--
pp = percentage points

About Xinxiang Tuoxin Pharmaceutical Co.Ltd.

SHE:301089 China Drug Manufacturers - Specialty & Generic
Market Cap
$404.05 Million
CN¥2.76 Billion CNY
Market Cap Rank
#13483 Global
#4029 in China
Share Price
CN¥21.82
Change (1 day)
+0.23%
52-Week Range
CN¥21.49 - CN¥38.04
All Time High
CN¥209.98
About

Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in China. It offers nucleoside (acid) products, such as pyrimidine series, purine series, and nucleotide series; nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, cytosine, 5-fluorocytosine, cytidine, uridine; an… Read more